Terence A. Kelly
Chief Executive Officer at Perception Neuroscience Holdings, Inc.
Terence A. Kelly active positions
Companies | Position | Start | End |
---|---|---|---|
Perception Neuroscience Holdings, Inc. | Chief Executive Officer | 2019-10-31 | - |
President | 2019-10-31 | - | |
Perception Neuroscience, Inc.
Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Chief Executive Officer | - | - |
Career history of Terence A. Kelly
Former positions of Terence A. Kelly
Companies | Position | Start | End |
---|---|---|---|
CARDAX, INC. | Director/Board Member | 2014-06-15 | 2021-07-31 |
Independent Dir/Board Member | 2014-06-15 | 2021-07-31 | |
CoMentis, Inc.
CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Chief Executive Officer | 2010-12-31 | 2016-12-31 |
President | 2010-12-31 | 2016-12-31 | |
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Corporate Officer/Principal | 1989-12-31 | 2008-12-31 |
Kelly Pharma Research Consulting LLC | Founder | - | - |
Cardax Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cardax Pharmaceuticals, Inc. develops proprietary small molecule therapies for large unmet medical needs. It develops proprietary small molecule therapies for large unmet needs where oxidative stress and inflammation play important causative roles-including cardiovascular disease, hepatitis, macular degeneration and many cancers. The company's proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers efficacy along with an outstanding safety profile, oral bioavailability and tissue selectivity. Cardax Pharmaceuticals was founded by David G. Watumull and Samuelf Lockwood in May 2006 and is headquartered in Honolulu, HI. | Director/Board Member | 2014-06-16 | - |
Training of Terence A. Kelly
Rensselaer Polytechnic Institute | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
The Leonard N Stern School of Business | Masters Business Admin |
Statistics
International
United States | 11 |
Operational
Chief Executive Officer | 3 |
Director/Board Member | 2 |
President | 2 |
Sectoral
Health Technology | 5 |
Consumer Services | 4 |
Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
CARDAX, INC. | Health Technology |
Private companies | 6 |
---|---|
Boehringer Ingelheim Corp.
Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Health Technology |
Cardax Pharmaceuticals, Inc.
Cardax Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cardax Pharmaceuticals, Inc. develops proprietary small molecule therapies for large unmet medical needs. It develops proprietary small molecule therapies for large unmet needs where oxidative stress and inflammation play important causative roles-including cardiovascular disease, hepatitis, macular degeneration and many cancers. The company's proprietary, synthetic, natural compound derivatives represent a novel treatment approach that offers efficacy along with an outstanding safety profile, oral bioavailability and tissue selectivity. Cardax Pharmaceuticals was founded by David G. Watumull and Samuelf Lockwood in May 2006 and is headquartered in Honolulu, HI. | Health Technology |
Kelly Pharma Research Consulting LLC | |
Perception Neuroscience Holdings, Inc. | |
CoMentis, Inc.
CoMentis, Inc. Pharmaceuticals: MajorHealth Technology CoMentis, Inc. focuses on developing drugs to treat various central nervous system disorders. Its research and development spectrum include BACE inhibitors and modulators of the a7 nicotinic acetylcholine receptor (NAChR). The company was founded by John P. Cooke and Muralitharan Kengatharan in 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Perception Neuroscience, Inc.
Perception Neuroscience, Inc. Medical/Nursing ServicesHealth Services Perception Neuroscience, Inc. operates as a biopharmaceutical company, focusing on developing therapies in Neuropsychiatry. The company was founded by Jonathan Sporn and Jay Kranzler and is headquartered in New York, NY. | Health Services |
- Stock Market
- Insiders
- Terence A. Kelly
- Experience